Perioperative safety of aprotinin in coronary artery bypass graft surgery: Is there life after BART?

Drug Safety

Volumn 31, Issue 7, 2008, Pages 557-560

  Augoustides, John G ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aprotinin, adverse reactions

Indexed keywords

AMINOCAPROIC ACID; APROTININ; LYSINE DERIVATIVE; TRANEXAMIC ACID;

ALLERGIC REACTION; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HUMAN; KIDNEY DISEASE; LOW DRUG DOSE; MORTALITY; NOTE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

APROTININ; CORONARY ARTERY BYPASS; HEMOSTATICS; HUMANS; PERIOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 45549102610     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831070-00001     Document Type: Note

References (22)

1. Mangano DT, Tudor JC, Dietzel C. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation: the risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-65
2. Augoustides J. Con: aprotinin should not be used in cardiac surgery with cardiopulmonary bypass. J Cardiothor Vasc Anesth 2007; 21: 302-4
3. Brown JR, Birkmeyer NJO, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007; 115: 2801-13
4. Henry DA, Carless PA, Moxey AJ, et al. Antifibrinolytic use for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007; 4: CD001886
5. Fergusson D, Glass KC, Hutton B, et al. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clin Trials 2005; 2: 218-30
6. Augoustides JG, Fleisher LA. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clin Trials 2005; 2: 231-2
7. Bayer HealthCare Pharmaceuticals. Important trasylol safety information. November 5, 2007 [online]. Available from URL: http://www.trasylol.com [Accessed 2008 May 27]
8. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319-31
9. Ray WA, Stein CM. The aprotinin story: is BART the final chapter? N Engl J Med 2008; 358: 2398-400
10. Kluth M, Lueth JU, Zittermann A, et al. Low-dose aprotinin use is not associated with adverse effects on safety variables in coronary artery bypass graft surgery. Drug Saf 2008; 31 (7): 617-26
11. Strouch ZY, Chaney MA, Augoustides JG, et al. Case 1-2008: one institution's decreasing use of aprotinin during cardiac surgery in 2006. J Cardiothorac Vasc Anesth 2008; 22: 139-46
12. Kincaid EH, Ashburn DA, Hoyle JR, et al. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery? Ann Thorac Surg 2005; 80: 1388-93
13. Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008; 358: 784-93
14. Schneeweiss S, Seeger JD, Landon J, et al. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008; 358: 771-83
15. Pagano G, Howell NJ, Freemantle N, et al. Bleeding in cardiac surgery: the use of aprotinin does not affect survival. J Thorac Cardiovasc Surg 2008; 135: 495-502
16. US Food and Drug Administration. FDA clinical advisory on aprotinin [online]. Available from URL: http://www.fda.gov/cder/infopage/aprotinin/ default.htm [Accessed 2008 May 27]
17. Dietrich W, Busley R, Kriner M. High-dose aprotinin in cardiac surgery: is high-dose enough? An analysis of 8281 cardiac surgical patients treated with aprotinin. Anesth Analg 2006; 103: 1074-81
18. Ferguson TB. Aprotinin: are there lessons learned. JAMA 297: 527-529
19. Ray WA. Learning from aprotinin-mandatory trials of comparative efficacy and safety needed. N Engl J Med 2008; 358: 840-2
20. Sundt TM. The demise of aprotinin: our share of the blame. J Thorac Cardiovasc Surg 2008; 135: 729-31
21. Apostolakis E, Panagopoulos H, Koletsis EN, et al. Influence of ultra-low dose aprotinin on thoracic surgical procedures: a prospective randomized trial. J Cardiothorac Surg 2008 Mar 24; 3: 14
22. Shuhaiber JH, Goldsmith K, Large SR, et al. Does perioperative use of aprotinin reduce the rejection rate in heart transplant recipients? Eur J Cardiothorac Surg 2008; 33 (5): 849-55